News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Alzheimer's Drug ARIA Monitoring: Real-World Study Results
(MedPage Today) -- Rates of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with lecanemab (Leqembi) in the real world were consistent with those seen in clinical trials, data from the LEADER study showed....
Free to read? Not known for this outlet.
Read at MedPage Today → Archived copy (17 Oct 2026), Internet ArchiveScientists discover why poor sleep may harm some brains more
A gene involved in the brain’s overnight cleaning system may change how strongly poor sleep affects Alzheimer’s-related brain changes. The findings point toward more personalized prevention strategies based on both genetics and sleep habits.
Read at ScienceDaily → Archived copy (1 Aug 2026), Internet ArchiveFDA Approves Label Update for Kisunla to Reduce ARIA-E Risk
The FDA approved a revised, more gradual titration dosing schedule for donanemab (Kisunla) based on the TRAILBLAZER-ALZ 6 study, which found the new regimen cut ARIA-E brain-swelling side effects by 41% at 24 weeks and 35% at 52 weeks without reducing amyloid-clearing efficacy.
Why it matters: A dosing change that meaningfully lowers a serious, sometimes fatal side-effect risk for patients on donanemab, without sacrificing the drug's benefit.
Free to read? Not known for this outlet.
Read at PharmExec (reporting Eli Lilly/FDA action) → Archived copy (11 Jun 2026), Internet ArchiveA gene guiding brain cell growth may regulate Alzheimer’s plaque size and toxicity
Plexin-B1 shapes glial networks around beta-amyloid plaques. An NIA-funded study has found that targeting it may improve plaque clearance and reduce brain inflammation.
Why it matters: Targeting Plexin-B1 may improve beta-amyloid plaque clearance and reduce brain inflammation, offering a potential path to regulate Alzheimer's plaque size and toxicity.
Read at NIH National Institute on Aging → Archived copy (2 Oct 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.